Resources | NITAG RESOURCE CENTER

2024 ∙ NACI

Interim guidance on the use of Imvamune® in the context of a routine immunization program

2024 ∙ NACI

Economic Evidence Supplementary Appendix to the Recommendations for Public Health Programs on the Use of Pneumococcal Vaccines in Children, Including the Use of 15-Valent and 20-Valent Conjugate Vaccines

2024 ∙ NACI

Recommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines

2023 ∙ Farrar, J. L. Childs, L. Ouattara, M. Akhter, F. Britton, A. Pilishvili, T. Kobayashi, M.

Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults

2023 ∙ ACIP

Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023

2023 ∙ NACI

Recommendations on the use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix

2023 ∙ NACI

Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines

2023 ∙ NACI

Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations

2022 ∙ Guzman-Holst, A. de Barros, E. Rubio, P. DeAntonio, R. Cintra, O. Abreu, A.

Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020

2022 ∙ Tantawichien, T. Hsu, L. Y. Zaidi, O. Bernauer, M. Du, F. Yamada, E. Kim, J. O. Sukarom, I.

Systematic literature review of the disease burden and vaccination of pneumococcal disease among adults in select Asia-Pacific areas